First Time Loading...

Editas Medicine Inc
NASDAQ:EDIT

Watchlist Manager
Editas Medicine Inc Logo
Editas Medicine Inc
NASDAQ:EDIT
Watchlist
Price: 5.68 USD 1.43% Market Closed
Updated: Apr 23, 2024

Intrinsic Value

EDIT's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. [ Read More ]

The intrinsic value of one EDIT stock under the Base Case scenario is 11.51 USD. Compared to the current market price of 5.68 USD, Editas Medicine Inc is Undervalued by 51%.

Key Points:
EDIT Intrinsic Value
Base Case
11.51 USD
Undervaluation 51%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Editas Medicine Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling EDIT stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Editas Medicine Inc

Provide an overview of the primary business activities
of Editas Medicine Inc.

What unique competitive advantages
does Editas Medicine Inc hold over its rivals?

What risks and challenges
does Editas Medicine Inc face in the near future?

Has there been any significant insider trading activity
in Editas Medicine Inc recently?

Summarize the latest earnings call
of Editas Medicine Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Editas Medicine Inc.

Provide P/S
for Editas Medicine Inc.

Provide P/E
for Editas Medicine Inc.

Provide P/OCF
for Editas Medicine Inc.

Provide P/FCFE
for Editas Medicine Inc.

Provide P/B
for Editas Medicine Inc.

Provide EV/S
for Editas Medicine Inc.

Provide EV/GP
for Editas Medicine Inc.

Provide EV/EBITDA
for Editas Medicine Inc.

Provide EV/EBIT
for Editas Medicine Inc.

Provide EV/OCF
for Editas Medicine Inc.

Provide EV/FCFF
for Editas Medicine Inc.

Provide EV/IC
for Editas Medicine Inc.

Show me price targets
for Editas Medicine Inc made by professional analysts.

What are the Revenue projections
for Editas Medicine Inc?

How accurate were the past Revenue estimates
for Editas Medicine Inc?

What are the Net Income projections
for Editas Medicine Inc?

How accurate were the past Net Income estimates
for Editas Medicine Inc?

What are the EPS projections
for Editas Medicine Inc?

How accurate were the past EPS estimates
for Editas Medicine Inc?

What are the EBIT projections
for Editas Medicine Inc?

How accurate were the past EBIT estimates
for Editas Medicine Inc?

Compare the revenue forecasts
for Editas Medicine Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Editas Medicine Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Editas Medicine Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Editas Medicine Inc compared to its peers.

Compare the P/E ratios
of Editas Medicine Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Editas Medicine Inc with its peers.

Analyze the financial leverage
of Editas Medicine Inc compared to its main competitors.

Show all profitability ratios
for Editas Medicine Inc.

Provide ROE
for Editas Medicine Inc.

Provide ROA
for Editas Medicine Inc.

Provide ROIC
for Editas Medicine Inc.

Provide ROCE
for Editas Medicine Inc.

Provide Gross Margin
for Editas Medicine Inc.

Provide Operating Margin
for Editas Medicine Inc.

Provide Net Margin
for Editas Medicine Inc.

Provide FCF Margin
for Editas Medicine Inc.

Show all solvency ratios
for Editas Medicine Inc.

Provide D/E Ratio
for Editas Medicine Inc.

Provide D/A Ratio
for Editas Medicine Inc.

Provide Interest Coverage Ratio
for Editas Medicine Inc.

Provide Altman Z-Score Ratio
for Editas Medicine Inc.

Provide Quick Ratio
for Editas Medicine Inc.

Provide Current Ratio
for Editas Medicine Inc.

Provide Cash Ratio
for Editas Medicine Inc.

What is the historical Revenue growth
over the last 5 years for Editas Medicine Inc?

What is the historical Net Income growth
over the last 5 years for Editas Medicine Inc?

What is the current Free Cash Flow
of Editas Medicine Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Editas Medicine Inc.

Financials

Balance Sheet Decomposition
Editas Medicine Inc

Current Assets 340.8m
Cash & Short-Term Investments 323.1m
Receivables 10.2m
Other Current Assets 7.5m
Non-Current Assets 158.3m
Long-Term Investments 104m
PP&E 45.7m
Other Non-Current Assets 8.6m
Current Liabilities 63.2m
Accounts Payable 8.3m
Accrued Liabilities 46.7m
Other Current Liabilities 8.2m
Non-Current Liabilities 86.8m
Other Non-Current Liabilities 86.8m
Efficiency

Earnings Waterfall
Editas Medicine Inc

Revenue
78.1m USD
Operating Expenses
-247.3m USD
Operating Income
-169.2m USD
Other Expenses
16m USD
Net Income
-153.2m USD

Free Cash Flow Analysis
Editas Medicine Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

EDIT Profitability Score
Profitability Due Diligence

Editas Medicine Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

Exceptional 1-Year Revenue Growth
ROIC is Increasing
Negative Revenue Growth Forecast
Negative 3-Years Revenue Growth
21/100
Profitability
Score

Editas Medicine Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

EDIT Solvency Score
Solvency Due Diligence

Editas Medicine Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
59/100
Solvency
Score

Editas Medicine Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

EDIT Price Targets Summary
Editas Medicine Inc

Wall Street analysts forecast EDIT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EDIT is 16.17 USD with a low forecast of 7.07 USD and a high forecast of 28.35 USD.

Lowest
Price Target
7.07 USD
24% Upside
Average
Price Target
16.17 USD
185% Upside
Highest
Price Target
28.35 USD
399% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

EDIT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

EDIT Price
Editas Medicine Inc

1M 1M
-23%
6M 6M
-9%
1Y 1Y
-28%
3Y 3Y
-85%
5Y 5Y
-79%
10Y 10Y
-65%
Annual Price Range
5.68
52w Low
5.49
52w High
11.47
Price Metrics
Average Annual Return 4.9%
Standard Deviation of Annual Returns 98.4%
Max Drawdown -94%
Shares Statistics
Market Capitalization 464.4m USD
Shares Outstanding 81 813 800
Percentage of Shares Shorted 28.1%

EDIT Return Decomposition
Main factors of price return

What is price return decomposition?

EDIT News

Other Videos

Company Profile

Editas Medicine Inc Logo
Editas Medicine Inc

Country

United States of America

Industry

Biotechnology

Market Cap

464.4m USD

Dividend Yield

0%

Description

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 264 full-time employees. The company went IPO on 2016-02-03. The firm is focused on developing transformative gene editing medicines to treat a range of serious diseases. The company has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The firm is focused on both in vivo gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and ex vivo gene-edited cell medicines, in which cells are edited with its technology. The firm's gene editing medicine programs include EDIT-101, EDIT-102, EDIT-103, EDIT-301 and EDIT-202.

Contact

MASSACHUSETTS
Cambridge
11 Hurley St
+16174019000.0
http://www.editasmedicine.com/

IPO

2016-02-03

Employees

264

Officers

President, CEO & Director
Dr. Gilmore O'Neill M.D.
Senior VP & Chief Medical Officer
Dr. Baisong Mei M.D., Ph.D.
Co-Founder & Scientific Advisory Board Member
Dr. David R. Liu Ph.D.
CFO & Executive VP
Mr. Erick J. Lucera C.F.A., CPA
Executive VP & Chief Scientific Officer
Dr. Linda C. Burkly Ph.D.
Corporate Communications & Investor Relations
Cristi Barnett
Show More
Executive VP & General Counsel
Ms. Charlene Stern J.D., Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one EDIT stock?

The intrinsic value of one EDIT stock under the Base Case scenario is 11.51 USD.

Is EDIT stock undervalued or overvalued?

Compared to the current market price of 5.68 USD, Editas Medicine Inc is Undervalued by 51%.